Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Bundred, Nigel; Porta, Nuria; Brunt, Adrian Murray; Cramer, Angela; Hanby, Andrew; M. Shaaban, Abeer; Rakha, Emad A.; Armstrong, Anne; Cutress, Ramsey I.; Dodwell, David; Emson, Marie A.; Evans, Abigail; M. Hartup, Sue; Horgan, Kieran; Miller, Sarah E.; McIntosh, Stuart A.; Morden, James P.; Naik, Jay; Narayanan, Sankaran; Ooi, Jane; Skene, Anthony I.; Cameron, David A.; Bliss, Judith M.

doi:10.1158/1078-0432.c.6532623

All Outputs (2)

Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2023)
Dataset
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., Shaaban, A. M., …Bliss, J. M. (2023). Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. [Dataset]. https://doi.org/10.1158/1078-0432.c.6532623.v1

Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included n... Read More about Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.

Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2023)
Dataset
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., M. Shaaban, A., …Bliss, J. M. (2023). Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. [Dataset]. https://doi.org/10.1158/1078-0432.c.6532623

Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included n... Read More about Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.